PROGRAM
All Times are ET
Program is subject to change
Saturday, February 3, 2024
| 7:50 am | Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, Harry W. Flynn, Jr., and Thomas A. Albini |
| Session I: OCTomics Moderators: Philip Rosenfeld, Giovanni Gregori, and Omer Trivizki Panelists: K. Bailey Freund, Amitha Domalpally, SriniVas Sadda, Omer Trivizki, Alessandro Berni, David Sarraf, Yuxuan Cheng, Jie Lu, Ruikang Wang, James Fujimoto, and Toshinori Murata |
|
| 8:00 | New Imaging Findings from High-Res OCT K. Bailey Freund |
| 8:10 | Trizonal Distribution of Drusen and SDD with En Face OCT Maps to Photoreceptor Density David Sarraf |
| 8:20 | Multimodal Assessment of OCT Biomarkers of GA and its Precursors Amitha Domalpally |
| 8:30 | Precursor Lesions for Development of Atrophy in AMD SriniVas R. Sadda |
| 8:40 | A Comparison Between the Grading of iRORA and cRORA on OCT B-Scans with the Grading of Persistent Hype transmission Defects on En Face OCT images Omer Trivizki |
| 8:50 | Algorithms to Detect and Quantify Drusen, Choroidal Hypertransmission Defects, and Hyperpigmentation Applicable to Both SD-OCTA and SS-OCTA Scans Philip J. Rosenfeld |
| 9:00 | SS-OCTA Imaging of High-Risk OCT Biomarkers that Predict Disease Progression in Intermediate AMD Alessandro Berni |
| 9:10 | Automated Segmentation and Quantification of Calcifying Drusen Applicable to Both SD-OCT and SS-OCT Scans Jie Lu |
| 9:20 | Automated Detection of Choroidal Hypertransmission Defects with Both SD-OCTA and SS-OCTA Scans Yuxuan Cheng |
| 9:30 | Automated Measurement of Outer Retinal Thickness as a Biomarker for Assessing AMD Progression Ruikang Wang |
| 9:40 | SS-OCT Angiography for Mapping Retinal Capillary Structure and Assessing Flow James G. Fujimoto |
| 9:50 | Leakage Detection Through OCT-Angiography Using Artificial Intelligence-Inferred Fluorescein Angiography Toshinori Murata |
| Session II: Non-Exudative AMD Moderators: Jaclyn L. Kovach, Zohar Yehoshua, and Philip J. Rosenfeld Panelists: Christine Curcio, Carel Hoyng, Lawrence Yannuzzi, Giovanni Staurenghi, Emily Y. Chew, Seung-Young Yu, Giuseppe Querques, and Pearse Keane |
|
| 10:00 | Early Onset AMD: Lessons to Learn Carel B. Hoyng |
| 10:10 | Zonal Resolution of Widespread Drusen Lawrence A. Yannuzzi |
| 10:20 | Lysolipids are Prominent in Subretinal Drusenoid Deposits Christine A. Curcio |
| 10:30 | The Importance of Basal Laminar Deposits in AMD Giovanni Staurenghi |
| 10:40 | Classification and Regression Tree (CART) Analyses for Intermediate Age-Related Macular Degeneration---AREDS/AREDS2 Emily Y. Chew |
| 10:50 | Impact of Risk Factors on Progression and Vision Impairment of Geographic Atrophy in a Korean Patient Cohort Seung-Young Yu |
| 11:00 | Predictors of GA Development in Type 3 MNV Treated with Anti-VEGF Therapy Giuseppe Querques |
| 11:10 | Foundation Models and AMD Pearse A. Keane |
| Session III: Emerging Therapies for Non-Exudative AMD Moderators: Ninel Z. Gregori, Philip J. Rosenfeld, and Raquel Goldhardt Panelists: Mario Saravia, Philip J. Rosenfeld, Robert Bhisitkul, Allen C. Ho, Byron L. Lam, Carl Danzig, Jeffrey S. Heier, Peter K. Kaiser, and Eleonora Lad |
|
| 11:20 | Balloon Angioplasty for AMD: An Update Mario Saravia |
| 11:30 | Optogenetics for Restoring Vision in Geographic Atrophy Secondary to Advanced AMD Allen C. Ho |
| 11:40 | AVD-104 for Geographic Atrophy: Glyco-Immunologic Modulation of Macrophage Activity Carl Danzig |
| 11:50 | Retinal Structure Improvements with OpRegen RPE Cell Therapy in a Phase I/IIa Study in Geographic Atrophy Allen C. Ho |
| 12:00 pm | Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy: Results of the ARCHER Study Jeffrey S. Heier |
| 12:10 | Elamipretide Update - Entering Phase 3 Peter K. Kaiser |
| 12:20 | LIGHTSITE III 24-Month Analysis: Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Eleonora Lad |
| Session IV: Visual FunctionTesting and Complement Inhibition for the Treatment of GA Moderators: Sander R. Dubovy, Zohar Yehoshua, and Philip J. Rosenfeld Panelists: Nadia K. Waheed, Michael S. Ip, Karl G. Csaky, Ursula Schmidt-Erfurth, Usha Chakravarthy, Arshad M. Khanani, David R. Lally, Justis P. Ehlers, Glenn J. Jaffe, Dilsher Dhoot, Roger A. Goldberg, and Nathan C. Steinle |
|
| 12:30 | Comparability of Functional Retinal Testing Across Devices in AMD Patients and Normal Controls Nadia K. Waheed |
| 12:40 | Functional Endpoints in Geographic Atrophy: An Analysis from the Chroma and Spectri Clinical Trials Michael S. Ip |
| 12:50 | The Use of High Density Focal Photopic Microperimetry to Follow Response to Anti-Complement Therapy in Patients with Geographic Atrophy Karl G. Csaky |
| 1:00 | AI in GA: How to Screen, Identify and Monitor Patients in the Real-World Ursula Schmidt-Erfurth |
| 1:10 | 2-year Expanded Efficacy Data from the GATHER 2 Trial Arshad M. Khanani |
| 1:20 | Safety Findings from the GATHER Program Including 2-year Results from the GATHER2 Trial David R. Lally |
| 1:30 | Functional Consequences of Avacincaptad Treatment in the GATHER Trials Usha Chakravarthy |
| 1:40 | Hypertransmission Defects and Ellipsoid Zone Integrity Dynamics in the GATHER Clinical Trials Justis P. Ehlers |
| 1:50 | Does Initial GA Growth Rate Predict GA Lesion Growth Rate and Response to Therapy at 2 years: 2-year Follow-up Data from GATHER 2 Glenn J. Jaffe |
| 2:00 | Update on Pegcetacoplan for the Treatment of Geographic Atrophy Dilsher Dhoot |
| 2:10 | Functional Benefits with Pegcetacoplan Roger A. Goldberg |
| 2:20 | An Anchored-Matching Adjusted Indirect Comparison of the Phase 3 Trials for GA: Pegcatacoplan vs. Avacincaptad Pegol Nathan C. Steinle |
| Session V: Real World Experience with Complement Inhibition for GA Moderators: Thomas A. Albini, Philip J. Rosenfeld, and Janet L. Davis Panelists: Nadia K. Waheed, Michael S. Ip, Ursula Schmidt-Erfurth, Karl G. Csaky, Usha Chakravarthy, Arshad M. Khanani, David R. Lally, Justis P. Ehlers, Glenn J. Jaffe, Mathew MacCumber, Omer Trivizki, Andre J. Witkin, Dilsher Dhoot, Roger A. Goldberg, Lawrence Singerman, Nathan C. Steinle, and Charles C. Wykoff |
|
| 2:30 | Management of Geographic Atrophy with Pegcetacoplan in Clinical Practice: First Time Data Presentation from a Large Multi-Center Study Mathew MacCumber |
| 2:40 | Defining Occlusive Retinal Vasculitis Thomas A. Albini |
| 2:50 | Retinal Vasculitis Following Intravitreal Pegcetacoplan: An Update from the ASRS ReST Committee Andre J. Witkin |
| 3:00 | Panel Discussion: Translating the Results of Clinical Trials to the Real-World Treatment of Late Nonexudative AMD |
| Session VI: Emerging Therapies for Exudative AMD Moderators: Luis J. Haddock, Stephen G. Schwartz, and Nicolas A. Yannuzzi Panelists: Mark R. Barakat, Xiaodong Sun, David Eichenbaum, Arshad M. Khanani, Charles C. Wykoff, Carl D. Regillo, Nancy Holekamp, Anat Lowenstein, and David M. Brown |
|
| 3:30 | KSI-501 Bispecific Anti-VEGF Anti-IL-6 Antibody Biopolymer Conjugate: First Time Results of the Multiple Ascending Dose Phase 1 Study Mark R. Barakat |
| 3:40 | Clinical Trails Evaluating LX102 Anti-VEGF Gene Therapy in Patients with Wet AMD Xiaodong Sun |
| 3:50 | Subretinal Delivery of RGX-314 for Neovascular AMD: A Phase 2 Pharmacodynamic Study David Eichenbaum |
| 4:00 | First Interim Results (24 weeks) for the Randomized Phase 2 Dose Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need Patients with nAMD Arshad M. Khanani |
| 4:10 | THE DAVIO 2 TRIAL: Topline Data from a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib in the Durasert E™ Technology) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration Charles C. Wykoff |
| 4:20 | THE DAVIO 2 TRIAL: Subgroup Data from a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib in the Durasert E™ Technology) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration Carl D. Regillo |
| 4:30 | Home OCT Guided Management of Patients with nAMD Nancy Holekamp |
| 4:40 | Longitudinal AI-based Fluid Quantification and its Implication for Remote Patient Monitoring Anat Loewenstein |
| 4:50 | Is 12 Weeks the New Norm? What Determines Why Some Patients Need More Frequent Intravitreal Dosing? David M. Brown |
| Session VII: Current Anti-VEGF Therapies for Exudative AMD and Retinal Vascular Diseases: High-Dose Aflibercept Moderators: Thomas A. Albini, Maura DiNicola, and Philip J. Rosenfeld Panelists: W. Lloyd Clark, Gemmy Cheung Chui Ming, Diana V. Do, and John A. Wells |
|
| 5:00 | 96-week Efficacy and Safety of Aflibercept 8 mg in nAMD: An Update from the PULSAR Study W. Lloyd Clark |
| 5:10 | Aflibercept 8mg for PCV Subgroup in the PULSAR Study Gemmy Cheung Chui Ming |
| 5:20 | Aflibercept 8mg for Diabetic Macular Edema: Update on the 96-Week Results of the PHOTON Study Diana V. Do |
| 5:30 | Aflibercept 8 mg: Safety Outcomes from the CANDELA, PULSAR, and PHOTON Studies John A. Wells |
| 5:40 | Discussion |
| Session VIII: Current Anti-VEGF Therapies for Exudative AMD and Retinal Vascular Diseases: Faricimab Moderators: Thomas A. Albini, Maura DiNicola, and Philip J. Rosenfeld Panelists: Jennifer Lim, Rishi Singh, Ramin Tadayoni, Robyn Guymer, and Arshad M. Khanani |
|
| 5:50 | Targeting Ang2 and VEGF - Biology, Pharmacokinetics and Latest Clinical Data in nAMD and DME Jennifer I. Lim |
| 6:00 | Emerging Imaging and Biological Markers Supporting Angiopoietin-2 in nAMD and DME Rishi Singh |
| 6:10 | Faricimab in RVO: 72-Week Results From the BALATON and COMINO Phase 3 Studies Ramin Tadayoni |
| 6:20 | Voyager Study- Update on Faricimab in the Real World Robyn Guymer |
| 6:30 | Insights from Clinical Practice - Review of First Year Experience with Faricimab in the Real World Arshad M. Khanani |
| 6:40 | Discussion |
| Session IX: Diabetic Retinopathy and Retinal Vascular Diseases Moderators: Harry W. Flynn, Jr., Justin H. Townsend, and Basil Williams Panelists: Jennifer K. Sun, Quan Dong Nguyen, Baruch Kuppermann, Robert Bhisitkul, David S. Boyer, Felipe Pereira, Veeral Sheth, Dante Pieramici, Peter A. Campochiaro, Darius M. Moshfeghi, and Martin Friedlander |
|
| 6:50 | OCT Angiography in Diabetic Retinopathy Harry W. Flynn, Jr. |
| 7:00 | Predictors of Diabetic Retinopathy Worsening on Ultrawide Field Imaging Jennifer K. Sun |
| 7:10 | OCS-01 for Diabetic Macular Edema: A New Perspective on Dexamethasone Quan Dong Nguyen |
| 7:20 | Intravitreal Sustained-Release Dexamethasone Implant for DME and RVO: Interim Results from the First In-Human Phase 2 RIPPLE-1 Trial Baruch Kuppermann |
| 7:30 | Subgroup analysis and effect of disease severity in the BEHOLD phase 2 study of UBX1325 in DM Robert Bhisitkul |
| 7:40 | RZ402: A Novel Orally Administered Plasma Kallikrein Inhibitor Targeting Diabetic Macular Edema David S. Boyer |
| 7:50 | Oral 3TC for Center-Involved Diabetic Macular Edema: A Randomized Clinical Trial Felipe Pereira |
| 8:00 | APX3330 Oral Treatment to Slow the Progression of Diabetic Retinopathy Using a Binocular DRSS Severity Scale as the Endpoint Veeral Sheth |
| 8:10 | The Path Forward for PDS: Technical Data Supporting Device Improvements and Septum Dislodgement Mitigation Dante Pieramici |
| 8:20 | The impact of Continuous Delivery of Ranibizumab with PDS on Retinal Nonperfusion in Diabetic Retinal Disease Peter Campochiaro |
| 8:30 | Combined Analysis of BUTTERFLEYE/FIREFLEYE NEXT Aflibercept for ROP Treatment Trials and the Emerging ROP Prevention Trials Darius M. Moshfeghi |
| 8:40 | What’s New with MacTel2? Martin Friedlander |
| 8:50 | Post-Program Test and Closing Remarks |
| 8:55 | Meeting Adjourns |